All In Biotech

Drug Trial Radar · NCT00675688

Study Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women

A Double-Blind, Randomized, Placebo- and Active-Controlled Safety and Efficacy Study of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women

Last checked: Nov 20, 2026Latest source record: May 12, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 3,544 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,544

Actual

Start

Apr 2002

Primary completion

Jan 2006

Study completion Jan 2006

Sponsor

Sponsor type
Industry
First posted
May 12, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 40 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective for the prevention of endometrial hyperplasia and for the prevention of osteoporosis in postmenopausal women.

Conditions

  • Endometrial Hyperplasia
  • Osteoporosis

Interventions

  • Bazedoxifene/Conjugate Estrogens (CE)Drug

  • RaloxifeneDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the effects of Bazedoxifene/Conjugate Estrogens (CE) combinations on the incidence of endometrial hyperplasia in postmenopausal women.Time frame: one year

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.